News - Bavarian Nordic
WEBSep 12, 2024 · Bavarian Nordic Announces First Half 2024 Results. August 21, 2024 | Company Announcements. Bavarian Nordic Receives 440,000 Dose Contract to Supply Smallpox and Mpox Vaccines for Undisclosed European Country. August 17, 2024 | …
News | Bavarian Nordic
WEBJun 10, 2022 · Bavarian Nordic Receives an Additional Order for JYNNEOS Smallpox and Monkeypox Vaccine from the U.S. Government . BARDA has ordered 500,000 doses of liquid-frozen JYNNEOS ® to be manufactured from existing bulk vaccine for delivery in 2022; Order brings the total U.S. inventory of liquid-frozen JYNNEOS to nearly 2 …
News - Bavarian Nordic
WEBInvestors. We are committed to providing our shareholders and the media with reliable and transparent information about our business, development programs and results in an open and timely manner. Read more. Annual Report 2023. News.
News - Bavarian Nordic
WEBU.S. Government Orders Another 2.5 Million Doses of Monkeypox Vaccines from Bavarian Nordic. Bavarian Nordic to supply an additional 2.5 million doses of JYNNEOS ® vaccine, bringing deliveries in 2022 and 2023 to a total of nearly 7 million doses.
News - Bavarian Nordic
WEBDec 6, 2021 · Bavarian Nordic Reports New Preclinical Data for COVID-19 Vaccine Confirming Potential for Broad Protection against SARS-CoV2 Variants
News | Bavarian Nordic
WEBNov 9, 2022 · Bavarian Nordic Announces Interim Results for the First Nine Months of 2022. COPENHAGEN, Denmark, November 9, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2022 and business progress for the third quarter of 2022.
Bavarian Nordic
WEBSep 18, 2024 · Bavarian Nordic - a pioneering force in vaccines – expanding our reach and impact through life-changing solutions. OUR LOCATIONS.
News | Bavarian Nordic
WEBMay 5, 2022 · Bavarian Nordic Reports Omicron Data from Phase 2 Trial of its COVID-19 Booster Vaccine Candidate. COPENHAGEN, Denmark, May 5, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today additional results from its Phase 2 clinical trial of ABNCoV2, a VLP-based, non-adjuvanted COVID-19 vaccine candidate. Data from subjects, who were previously ...
News | Bavarian Nordic
WEBOct 25, 2023 · Pending approval of the updated recommendations, Bavarian Nordic is targeting a commercial launch of JYNNEOS in the U.S. in the first half of 2024. This represents the second national recommendation for Bavarian Nordic’s mpox vaccine in adult risk groups following a similar endorsement by the Standing Committee for Vaccination (STIKO) in ...
News | Bavarian Nordic
WEBMay 8, 2024 · Bavarian Nordic remains on track for submission of the MAA in the first half of 2024. Bavarian Nordic hosted a capital markets day in February, providing an update on the Company’s business and strategy, including the discontinuation of its …